SV2009003324A - Preparacion farmaceutica para reducir la endometriosis - Google Patents
Preparacion farmaceutica para reducir la endometriosisInfo
- Publication number
- SV2009003324A SV2009003324A SV2009003324A SV2009003324A SV2009003324A SV 2009003324 A SV2009003324 A SV 2009003324A SV 2009003324 A SV2009003324 A SV 2009003324A SV 2009003324 A SV2009003324 A SV 2009003324A SV 2009003324 A SV2009003324 A SV 2009003324A
- Authority
- SV
- El Salvador
- Prior art keywords
- pharmaceutical composition
- endometriosis
- effectiveness
- negative influence
- bone density
- Prior art date
Links
- 201000009273 Endometriosis Diseases 0.000 title abstract 3
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000037182 bone density Effects 0.000 abstract 2
- 208000002874 Acne Vulgaris Diseases 0.000 abstract 1
- 206010000496 acne Diseases 0.000 abstract 1
- 230000002280 anti-androgenic effect Effects 0.000 abstract 1
- 230000004097 bone metabolism Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 230000016087 ovulation Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
UNA COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO DE ENDOMETRIOSIS SIN REDUCIR LA DENSIDAD ÓSEA CONTIENE UN GESTÁGENO CON EFICACIA ANTIANDROGÉNICA, CON PREFERENCIA 17ALFA-CIANOMETIL-17-BETA-HIDROXIESTRA-4,9-DIEN-3-ONA (DIENOGEST), ACETATO DE CIPROTERONA O ACETATO DE CLOROMADINONA EN UNA DOSIS DIARIA QUE ES COMO MÁXIMO EL DOBLE DE LA DOSIS INHIBIDORA DE LA OVULACIÓN, JUNTO CON UNO O VARIOS EXCIPIENTES/PORTADORES FARMACÉUTICAMENTE ACEPTABLES. LA COMPOSICIÓN FARMACÉUTICA SEGÚN LA INVENCIÓN PRODUCE TANTO LA REDUCCIÓN DE LA ENDOMETRIOSIS COMO TAMBIÉN LA AUSENCIA DE INFLUENCIA NEGATIVA SOBRE EL METABOLISMO ÓSEO Y DE LA DENSIDAD ÓSEA Y AL MISMO TIEMPO PUEDE MANTENER EN UNA MEDIDA TOLERABLE LOS EFECTOS COLATERALES CONOCIDOS DE LOS MEDICAMENTOS CONVENCIONALES (POR EJEMPLO, SOFOCACIONES, ACNÉ, INFLUENCIA NEGATIVA DEL PERFIL LIPÍDICO). LA COMPOSICIÓN FARMACÉUTICA ES POR ELLO APROPIADA PARA LA APLICACIÓN A LARGO PLAZO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07004202A EP1977752A1 (de) | 2007-03-01 | 2007-03-01 | Pharmazeutische Zubereitung zur Verminderung der Endometriose |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2009003324A true SV2009003324A (es) | 2009-10-02 |
Family
ID=38045772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2009003324A SV2009003324A (es) | 2007-03-01 | 2009-07-03 | Preparacion farmaceutica para reducir la endometriosis |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1977752A1 (es) |
| JP (1) | JP2010520159A (es) |
| KR (1) | KR20090119829A (es) |
| CN (1) | CN101583364A (es) |
| AU (1) | AU2008221012A1 (es) |
| BR (1) | BRPI0806598A2 (es) |
| CA (1) | CA2673936A1 (es) |
| CO (1) | CO6190606A2 (es) |
| CR (1) | CR10912A (es) |
| DO (1) | DOP2009000171A (es) |
| EA (1) | EA200900829A1 (es) |
| EC (1) | ECSP099482A (es) |
| MA (1) | MA31162B1 (es) |
| MX (1) | MX2009007259A (es) |
| NZ (1) | NZ577761A (es) |
| SV (1) | SV2009003324A (es) |
| TN (1) | TN2009000263A1 (es) |
| WO (1) | WO2008104342A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101874806A (zh) * | 2009-04-29 | 2010-11-03 | 北京本草天源药物研究院 | 一种地诺孕素固体制剂 |
| CN102670519B (zh) * | 2011-03-16 | 2014-06-11 | 重庆莱美药业股份有限公司 | 一种可快速溶出的地诺孕素口服制剂及其制备方法 |
| CN103304619B (zh) * | 2013-06-08 | 2015-12-02 | 西藏海思科药业集团股份有限公司 | 一种地诺孕素化合物 |
| WO2025124422A1 (zh) * | 2023-12-13 | 2025-06-19 | 长春金赛药业有限责任公司 | 一种原位皮下植入的女性激素调节组合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426601A1 (de) * | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| EP1535618A1 (en) * | 2003-11-26 | 2005-06-01 | Schering Aktiengesellschaft | Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions |
| MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
| DE102004026679A1 (de) * | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonales Kontrazeptivum enthaltend eine Kombination aus Ethinylestradiol und Chlormadinonacetat |
| EP1655031A1 (de) * | 2004-10-08 | 2006-05-10 | Schering AG | Dienogest enthaltendes Langzeit-Verfahren zur Empfängnisverhütung |
-
2007
- 2007-03-01 EP EP07004202A patent/EP1977752A1/de not_active Withdrawn
-
2008
- 2008-02-23 MX MX2009007259A patent/MX2009007259A/es unknown
- 2008-02-23 CN CNA2008800023330A patent/CN101583364A/zh active Pending
- 2008-02-23 NZ NZ577761A patent/NZ577761A/en not_active IP Right Cessation
- 2008-02-23 EP EP08707797A patent/EP2059248A1/de not_active Ceased
- 2008-02-23 BR BRPI0806598-5A patent/BRPI0806598A2/pt not_active IP Right Cessation
- 2008-02-23 WO PCT/EP2008/001451 patent/WO2008104342A1/de not_active Ceased
- 2008-02-23 CA CA002673936A patent/CA2673936A1/en not_active Abandoned
- 2008-02-23 EA EA200900829A patent/EA200900829A1/ru unknown
- 2008-02-23 AU AU2008221012A patent/AU2008221012A1/en not_active Abandoned
- 2008-02-23 KR KR1020097014169A patent/KR20090119829A/ko not_active Withdrawn
- 2008-02-23 JP JP2009551120A patent/JP2010520159A/ja active Pending
-
2009
- 2009-06-24 TN TNP2009000263A patent/TN2009000263A1/fr unknown
- 2009-07-03 SV SV2009003324A patent/SV2009003324A/es not_active Application Discontinuation
- 2009-07-03 CR CR10912A patent/CR10912A/es unknown
- 2009-07-03 DO DO2009000171A patent/DOP2009000171A/es unknown
- 2009-07-03 CO CO09068629A patent/CO6190606A2/es not_active Application Discontinuation
- 2009-07-03 EC EC2009009482A patent/ECSP099482A/es unknown
- 2009-08-04 MA MA32138A patent/MA31162B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2059248A1 (de) | 2009-05-20 |
| JP2010520159A (ja) | 2010-06-10 |
| DOP2009000171A (es) | 2009-08-31 |
| CN101583364A (zh) | 2009-11-18 |
| MA31162B1 (fr) | 2010-02-01 |
| NZ577761A (en) | 2012-03-30 |
| ECSP099482A (es) | 2009-08-28 |
| EP1977752A1 (de) | 2008-10-08 |
| EA200900829A1 (ru) | 2010-02-26 |
| CA2673936A1 (en) | 2008-09-04 |
| WO2008104342A1 (de) | 2008-09-04 |
| CO6190606A2 (es) | 2010-08-19 |
| AU2008221012A1 (en) | 2008-09-04 |
| CR10912A (es) | 2009-08-13 |
| BRPI0806598A2 (pt) | 2014-05-06 |
| TN2009000263A1 (en) | 2010-10-18 |
| MX2009007259A (es) | 2009-07-10 |
| KR20090119829A (ko) | 2009-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| MX2009010289A (es) | Composiciones para administracion nasal. | |
| MX392839B (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| UY33343A (es) | Formas de dosificación sólidas orales con dosis muy bajas para la hrt | |
| NI201100091A (es) | Tratamiento de pirfenidona para pacientes con función hepática atípica. | |
| MX2020001550A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX2012003551A (es) | Tabletas transformables via oral. | |
| MX2015009772A (es) | Moduladores de receptores nmda de espiro-lactama y sus usos. | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
| MX373666B (es) | Compensador de grosor de tejido que comprende una pluralidad de capsulas. | |
| CL2008002999A1 (es) | Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon. | |
| CL2007003604A1 (es) | Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer. | |
| ECSP088123A (es) | Anticoncepcion oral con trimegestona | |
| CO6300964A2 (es) | Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| PE20121520A1 (es) | Formulacion farmaceutica que comprende ranolazina y dronedarona en el tratamiento de fibrilacion auricular | |
| BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
| SV2009003324A (es) | Preparacion farmaceutica para reducir la endometriosis | |
| UY32650A (es) | Medicamento para la administración oral que contiene al menos un esterógeno y/o al menos un gestágeno y al menos una cepa de bacterias probióticas | |
| CO2019000604A2 (es) | Composición vaginal que comprende una combinación de estrógeno y vitamina d | |
| GT200900296A (es) | Composición farmacéutica que comprende la combinación de un agente anti inflamatorio no esteroideo y un agente anticonvulsivante. | |
| CL2016001707A1 (es) | Tratamiento de trastornos congnitivos con (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma (div. sol. 1178-11). | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| ES2325291A1 (es) | "uso de un extracto de silybum marianum" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Lapse |